Savara Inc
SVRA · XNASCIK 1160308fmd_0W9BQBVH854GACBN2VWM2A8F24Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 1997 to Sep 30, 2026, 79 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | 0 | 0 | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 8 | 19 | 37 | 39 | 35 | 29 | 28 | 44 | 78 | 81 |
| Selling, general and administrative | 9 | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 11 | 30 | 70 | 79 | 50 | 41 | 39 | 60 | 103 | 124 |
| Operating income | (11) | (30) | (70) | (79) | (49) | (41) | (39) | (60) | (103) | (124) |
| Interest expense | 0 | 1 | – | – | – | – | – | – | – | – |
| Interest and investment income | 0 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (3) | 1 | 1 | (0) | (2) | 1 | 5 | 7 | 5 |
| Income before taxes | (11) | (33) | (69) | (78) | (50) | (43) | (38) | (55) | (96) | (119) |
| Income tax expense | (0) | (4) | (7) | – | – | – | – | – | 0 | 0 |
| Net income from continuing operations | (11) | (30) | (62) | – | – | – | – | – | (96) | (119) |
| Net income | (11) | (30) | (62) | (78) | (50) | (43) | (38) | (55) | (96) | (119) |
| Net income to common shareholders | (11) | (31) | (62) | (78) | (50) | (43) | (38) | (55) | (96) | (119) |